Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Dr. Rakesh Suri, a cardiothoracic surgeon at Corewell Health, shares details about a groundbreaking robotic mitral valve ...

The data are observational but intuitive, say experts. Further work might define where T-TEER’s greatest benefit lies.

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy and efficiency.

Every year, more than 5 million people in the U.S. are diagnosed with heart valve disease, but this condition has no ...

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research led by the University of Bristol ...

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research has found.